FMC Corporation Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

GAAP Net Sales: $542 million, a 49% decline year-over-year, primarily due to significant one-time actions in India.

Revenue Excluding India: $961 million, down 4% year-over-year, driven by a 6% price decline but a 2% increase in volume.

Adjusted EBITDA: $236 million, with a margin of approximately 25%, reflecting a 17% increase year-over-year.

Adjusted EPS: $0.89, up 30% from the prior year.

Free Cash Flow: Negative $233 million for Q3, with a full-year guidance now adjusted to negative $200 million to $0.

Net Debt: Approximately $4.0 billion, with a gross debt to trailing 12-month EBITDA ratio of 5x.

2Strategic Updates and Business Highlights

FMC is focusing on becoming a pure-play agricultural sciences company, with a strong pipeline of innovative technologies.

Actions taken to address inventory issues in India included product returns and pricing credits to distributors.

The company is initiating a strategic review of its manufacturing footprint to enhance cost competitiveness, particularly for non-IP protected products.

FMC is investing in additional routes to market in Brazil, targeting large soybean and corn growers, with positive early results.

3Forward Guidance and Outlook

Q4 Sales Guidance: Expected to be between $1.12 billion and $1.22 billion, representing a 2% increase at the midpoint on a like-for-like basis.

Q4 Adjusted EBITDA Guidance: Projected between $265 million and $305 million, a decline of 16% at the midpoint.

Full-Year Revenue Guidance: Now expected to be between $3.92 billion and $4.02 billion.

Adjusted EPS Guidance: Forecasted to be $2.92 to $3.14 for the full year.

4Bad News, Challenges, or Points of Concern

Sales were below expectations, particularly in Latin America, due to constrained credit and increased competition from generics.

The company is facing pricing pressure, especially in Latin America, where generics are gaining market share due to favorable registration conditions.

Free cash flow guidance has been significantly reduced due to lower cash from operations and collection delays, particularly in Latin America.

The company reported a GAAP net loss of $569 million, largely due to charges related to the India business held for sale.

Concerns about maintaining investment-grade ratings were raised, with discussions ongoing regarding financial covenants.

5Notable Q&A Insights

Management acknowledged that the primary driver for reduced cash flow guidance was collection delays, exacerbated by liquidity constraints in Latin America.

The sale price for the India business is estimated at $450 million, with strong interest from both local and international buyers.

Management remains committed to maintaining investment-grade ratings but recognizes current metrics are not aligned; they are focused on cash management and debt reduction.

There is speculation on potential partnerships for new active ingredients, but selling any close-to-commercialization products is currently not on the table.

The company is reassessing its manufacturing costs and may adjust pricing strategies in response to competitive pressures, particularly concerning Rynaxypyr. Overall, FMC is navigating a challenging market environment while implementing strategic initiatives to enhance competitiveness and manage costs effectively.